The disruption of the endothelium is a prelude to the evolution of arteriosclerosis. Nitric 
INTRODUCTION
The evolution of cardiovascular disease is triggered by the dysfunction of the endothelial cell.
The invasion into the intima of the vessel wall by While NO has a major role in maintaining vasorelaxation, other molecules such as prostacyclin and activators of adenosine triphosphate (ATP) and calcium-sensitive potassium channels also contribute to a lesser extent to the process.
Admittedly a decrease in the bioactivity of NO leads to endothelial dysfunction.
Pro-inflammatory Mediators
The bioactivity of NO is affected by a variety of pro-inflammatory mediators. The capacity of NO to inhibit the activity of the transcription factor NF-kB can be overwhelmed by excess of hydrogen peroxide (H2Oz) and superoxide anions (Oz-) that can inactivate NO (6). H202 can also activate other pro-inflammatory mediators such as early growth response factor (erg) -1 and activator protein (AP) -1 (7, 8) . Hydroxyl radicals and peroxynitrite which is formed by the oxidation of NO by superoxide anions and free radicals are proinflammatory(6). Indeed the key for the modulation of the activity of pro-inflammatory mediators is the inhibition by NO of the transcription factor NF-kB.
The latter can induce the synthesis of pro-inflammatory cytokines and growth factors (9) . In addition to NO other antioxidants such as glutathione, catalase, superoxide dismutase protect the endothelium from the assault of pro-inflammatory oxidants. Antioxidant therapy with vitamins C and ~-tocopherol the biologically active form of vitamin E, and the cholesterol lowering drug Probucol have been shown to protect low density lipoprotein (LDL) from oxidation and in turn the progression of atherosclerosis (10) (11) (12) (13) .
Relationship between Chronic Infectious Processes and Atherosclerosis
Infectious agents such as cytomegalovirus, chlamydia pneumoniae and herpes virus have been suggested as playing a role in the atherogenic process (14, 15).
In a study of patients who developed narrowing of blood vessel lumen or restenosis after undergoing coronary angioplasty procedure, the presence of increased amounts of tumor suppressor protein p53 and human cytomegalovirus (HCMV) was reported in 23 of the 60 restenosis lesions (38%) that were examined (14) . Cultured smooth muscle cells from these restenosis lesions also expressed HCMV protein IE84 and increased amounts of p53. It has been postulated that HCMVthrough the binding of its protein IE84 to p53 inhibits the function of p53, thus leading to restenosis (14) .
Chlamydia pneumoniae has been detected by both immunohistochemical staining and the polymerase chain reaction (PCR) in tissue specimens taken from patients with coronary artery lesions (15) .
In a study conducted on 23 fresh tissue specimens taken from patients with primary coronary artery lesions and 15 specimens from patients who had restenosis, chlamydia pneumoniae was detected in 20 of the 38 specimens(15). The organism was confined to macrophages and was seen more frequently in tissue specimens from patients who had restenosis than those who had pdmary lesions. There have been reports of the association of small dense LDL particles with the incidence of coronary artery disease and the risk of myocardial infarction (18, 19) .
By nondenaturing polyacrylamide gel electrophoresis of plasma, individuals can be classified according to their LDL diameter into one of the three patterns (19) . Large LDL particles with a peak particle diameter usually larger than 26. Increased tdglyceride levels with the consequent increase in small dense LDL particles, and a decrease in high-density lipoprotein cholesterol (HDL-C) taken together increase the risk for myocardial infarction (19) .
The association of small dense LDL particles with the incidence of CAD stems from its increased susceptibility to oxidation (17) . Furthermore, these small dense LDL particles are cleared slowly from the plasma as a consequence of its poor binding to the LDL receptor.
The increased risk of small dense LDL for CAD is reported to be twice as high towards the clinical onset of CAD, in contrast to the earlier stages of atherosclerosis where LDL-C level is the most important risk factor (17, 20) . Incidentally, the increased tendency to thrombosis due to the increase in the activity of both the coagulation factor VII and plasminogen activator inhibitor-1 (PAl) the fibrinolytic inhibitor, is associated with increased triglyceride levels in plasma (17) . Thus the apo B component of small dense LDL, HDL-C and triglyceride levels are important in the later stages of atherosclerosis (17) .
Role of Oxidized LDL in Atherogenesis
As noted earlier, small dense LDL particles are more susceptible to oxidation. LDL sequestered within the subendothelial space of the arterial intima undergoes mild pemxidation of its polyunsaturated fatty acids (PUFAs) which is free radical mediated, to become minimally modified. This minimally modified LDL (MM-LDL) is susceptible to uptake by the LDL receptor (21) . Vitamin B6, B12 and folate supplementation can lower plasma homocysteine levels and protect the patient from cardiovascular disease. Indeed in a large prospective cohort study of 80,082 female nurses over a 14 year period itwas concluded that a daily intake of 400 pg folate and 3 mg vitamin 136 (Pyridoxal) was required to minimize cardiovascular mortality and morbidity (31) . In this study it was noted that among women with the highest folate intakes, moderate consumption of alcohol considerably decreased cardiovascular risk.
Measurement of Homocysteine

70% of circulating homocysteine is protein-bound.
The remainder is in the form of free oxidized and reduced spedes and the mixed disulfides of cysteinehomocysteine. The reduced or sulfahydryl form is referred to as homocysteine while the oxidized or disulfide form is called homocystine. Total homocysteine levels in plasma is a sum of both protein-bound and other forms mentioned above (32, 33) . In healthy subjects total homocysteine (tHcy) levels are usually in the range of 5 to 15pmol/L(33).
Methods for measurement of homocysteine range from high performance liquid chromatography (HPLC)) with fluorescence detection which is widely used, to procedures based on gas chromatographymass spectrometry (GC-MS) and enzyme immunoassay.
To the laboratorian the measurement of homocysteine presents challenges since this amino acid continues to be formed in the cell even after (35) . These high risk patients should be on an optimum daily intake of 400 pg folic acid, 2 mg vitamin B6 and 6pg of vitamin B12 and should be monitored for effect of therapy by following homocysteine levels in plasma (35) .
Laboratories using serum should centrifuge the blood as soon as the specimen has clotted whicn is usually thirty minutes, and separate serum from cells. Immunological methods for the measurement of LP(a) rely upon antibodies raised to the apo(a) portion of LP(a). The standardization of these assays has been problematic due to differences in assay design and calibration. 20 out of 40 assay systems evaluated in a standardization study were found to be non optimized (38) .
Clearly along with the standardization efforts, more longitudinal studies using a standardized assay are needed to establish definitively the relationship between increased plasma LP(a) levels and the risk of coronary heart disease.
Markers of Myocardial Damage
Laboratory diagnosis of myocardial infarction (MI) has traditionally been based on the measurement of enzymes and proteins released into the blood stream by the injured myocardium.
Myoglobin because of its low molecular mass Finally, non-specific laboratory markers such as c-reactive protein and serum amyloid A protein may be useful in identifying patients at risk of developing acute coronary events due to unstable coronary plaques (47) .
Conclusion
Markers of myocardial disease are useful for predicting the risk and for instituting appropriate therapy to reduce the incidence of cardiovascular damage and mortality. Emerging specific laboratory markers for detection of myocardial damage can be combined with non-specific markers that are released REFERENCES earlier following M I so that prompt thrombolytic therapy can be instituted to perfuse and selvage the damaged myocardium.
It is to be hoped that advances in molecular genetics will assist in identifying families that are at risk for cardiovascular disease. We already know that a mutation causing replacement of arginine at residue 
